Smith, 7, diagnosed with a rare blood disorder, receives a life-saving stem cell transplant from his father, Matt, offering ...

Rates of grade III/IV acute GVHD at 3 months were 3% with cyclophosphamide-cyclosporin prophylaxis and 10% with standard ...

Haematology's profound transformation offers new hope through advanced diagnostics, personalized medicine, and the noble act ...

Join Drs Tania Jain and Rachel Salit as they explore evolving definitions of remission, relapse monitoring, and ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

Macadamia nuts have a rich nutritional profile. They are packed with healthy fats, which serve as a steady and long-lasting ...

INmune Bio's XPro1595 targets soluble TNF for Alzheimer's. Phase 2 results could reshape inflammatory disease treatment.

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...